| General information |
| Database: | DB00595 |
| Objective: | Angiogenesis is crucial for glioblastoma growth, and antivascular endothelial growth factor agents are widely used in recurrent glioblastoma patients. The number of circulating endothelial cells (CECs) is a surrogate marker for endothelial damage. they assessed their kinetics and explored their prognostic value in patients with recurrent glioblastoma. |
| Authors: | Beije N, et al |
| Title: | Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch NeuroOncology Group BELOB trial. |
| Journal: | Br J Cancer. |
| Year: | 2015 |
| PMID: | 26042933 |
| Trial Design |
| Clinical Trial Id: | NA |
| Agent: | bevacizumab
|
| Target: | Vascular endothelial growth factor
|
| Cancer Type: | Tumors of the nervous system |
| Cancer Subtype: | glioblastoma |
| Therapy Type: | com |
| Therapeutic Combination Type: | 2 |
| Therapeutic Combination Content: | bevacizumab+lomustine |
| Study Type: | the randomised multicentrephase II trial |
| Key Patients Feature: | patients with recurrent glioblastoma |
| Biomarker: | CECs |
| Biomark Analysis: | Absolute CEC numbers in patients receiving bevacizumab plus lomustine or bevacizumab single agent were not associated with OS. |
| Control Group Info: | singleagent bevacizumab or lomustine, or bevacizumab plus lomustine |
| Treatment Info: | patients were randomised to receive singleagent bevacizumab or lomustine, or bevacizumab plus lomustine. Before treatment, after 4 weeks and after 6 weeks of treatment, CECs were enumerated. |
| Primary End Point: | the kinetics and prognostic relevance of CECs |
| Secondary End Point: | NA |
| Patients Number: | 141 |
| Trial Results |
| DLT_MTD: | NA |
| Objective Response Rate: | NA |
| Disease Control Rate: | NA |
| Median Time to Progression: | NA |
| Median PFS A vs. C: | NA |
| Median OS A vs. C: | NA |
| Adverse Event(agent arm): | NA |
| Conclusions: | CEC numbers increased during treatment with bevacizumab plus lomustine but not during treatment with either agent alone, suggesting that this combination induced the greatest vascular damage. Although the absolute number of CECs was not associated with OS in patients treated with bevacizumab either alone or in combination, they could serve as a marker in glioblastoma patients receiving lomustine single agent. |